-
Cefepime Beyond Coverage: A Translational Framework
2026-09-29
Cefepime (BMY-28142) is more than a broad-spectrum comparator: it can help translational researchers connect cell-wall inhibition, exposure over time, resistance adaptation, blood-brain barrier penetration, and neurotoxicity boundaries. This article outlines a practical framework for positioning Cefepime in bacterial infection models and central nervous system infection research without confusing product attributes with direct clinical evidence.
-
Ferroptosis Signature and Atorvastatin in HCC
2026-09-28
Wang and colleagues combined TCGA-based ferroptosis-related gene analysis with drug-signature screening to build a four-gene prognostic model and nominate atorvastatin for hepatocellular carcinoma (HCC). Their cell and animal experiments support atorvastatin-associated ferroptosis and reduced HCC growth and migration, while leaving clinical efficacy and the signature’s broader validation unresolved.
-
Benzyl Quinolone Carboxylic Acid (BQCA) in Cell Assays
2026-09-27
A practical guide to using Benzyl Quinolone Carboxylic Acid (BQCA), SKU C3869, to investigate M1 receptor signaling without mistaking a mechanistic probe for a viability reagent. It covers assay controls, concentration planning, interpretation of BRET findings, and evidence-based product selection.
-
SkQ1 Separates Mitochondrial Apoptosis from Muscle Atrophy
2026-09-26
In a mouse model of metastatic ovarian cancer, SkQ1 reduced late-stage mitochondrial hydrogen peroxide emission and caspase-9/-3 activity in gastrocnemius muscle, but did not prevent muscle atrophy. The findings distinguish changes in apoptotic signaling from changes in muscle structure and do not support a causal role for the measured mitochondrial pathways in atrophy of this muscle type.
-
Regorafenib Reduces RRM2 in Melanoma
2026-09-26
A 2024 iScience study links Regorafenib’s effects in melanoma to reduced RRM2 and altered ERK/E2F3 signaling, alongside lower malignant phenotypes and increased apoptosis. Cell-based experiments, RRM2 perturbation and rescue, and in vivo validation provide a mechanistic framework for further cancer biology research, while leaving clinical relevance and direct target engagement to be established.
-
In Vivo CD19 CAR T Cells for Lupus: Mouse Study
2026-09-25
This study reports an in vivo approach that uses CD5-targeted lipid nanoparticles to deliver CD19-directed CAR mRNA and generate functional CAR T cells in lupus-prone mice. The treatment depleted disease-associated B-cell populations and improved antibody, inflammatory, and tissue-damage measures without ex vivo cell manufacturing or lymphodepletion, while leaving important questions about delivery specificity, durability, and translation to people unresolved.
-
Thiothixene: Linking Pharmacology to Macrophage Assays
2026-09-25
Thiothixene is a typical antipsychotic agent with both established dopamine-receptor pharmacology and a reported macrophage efferocytosis effect. This article connects a human drug-interaction study to practical assay interpretation while clarifying what the evidence does—and does not—support.
-
Novobiocin Sodium: Protoplast Assay Workflows
2026-09-24
Use Novobiocin Sodium to test how bacterial DNA replication relates to protoplast enlargement, membrane expansion, and vacuole formation—not simply to measure growth inhibition. A time-resolved workflow combining microscopy and qPCR helps separate early effects from responses after vacuoles have formed.
-
EZ Cap™ Mouse IL-7 mRNA: Assay Design Guide
2026-09-24
Explore how EZ Cap™ Mouse IL-7 mRNA (m1Ψ, HA tag) can support controlled IL-7 expression studies, with practical guidance for selecting controls and validating readouts. A key evidence boundary distinguishes this reagent from a retinal angiogenesis study that did not test IL-7.
-
Fasudil (HA-1077) HCl: ROCK Assay Workflows
2026-09-23
Build more interpretable ROCK experiments with Fasudil (HA-1077) HCl across proliferation, migration, and apoptosis assays. This guide combines dose-finding, pathway validation, Hippo-signaling context, and practical troubleshooting for cancer and cell-injury models.
-
Surfactant-Derived LNPs Deliver mRNA to Macrophages
2026-09-22
Huang et al. developed a dual-component lipid nanoparticle system based on a surfactant-derived lipid and a fusogenic lipid for delivering mRNA to difficult-to-transfect macrophages. The study shows that selected quaternary ammonium chemistry can support mRNA condensation, nuclease protection, intracellular delivery, and favorable biocompatibility without a PEGylated lipid.
-
Telatinib (BAY 57-9352) Assay Guide
2026-09-22
This scenario-driven guide explains how Telatinib (BAY 57-9352), SKU A8550, can support reproducible viability, proliferation, invasion, and angiogenesis experiments. It connects receptor-level potency data with practical DMSO handling, dose optimization, phenotype interpretation, and evidence-based product selection.
-
Regorafenib Workflows for Cancer Biology Research
2026-09-21
Regorafenib (BAY 73-4506) supports integrated studies of kinase signaling, angiogenesis, migration, invasion, and melanoma-associated RRM2 biology. This practical guide connects formulation and assay design with troubleshooting strategies for cell systems and tumor xenograft models.
-
ZCL278: Selective Cdc42 Inhibitor Guide
2026-09-21
ZCL278 is a selective Cdc42 inhibitor for mechanistic studies of cell motility, neuronal morphology, and Cdc42 signaling. Product data report Cdc42 binding with a Kd of 11.4 μM and activity in cancer, neuronal, and fibroblast models, while kidney-fibrosis evidence supports Cdc42 as a pathway target rather than establishing ZCL278 as an antifibrotic treatment.
-
Fosinopril Sodium Workflows for ACE Research
2026-09-20
Build reproducible ACE inhibition, hypertension research, and translational cardiovascular workflows with a phosphinic acid prodrug designed for zinc-site engagement. This guide connects biochemical assay control with renal hemodynamics modulation, oral exposure studies, and clinically informed endpoint selection.